Biodyne Co

Biodyne Co FCF per Share

The Free Cash Flow per Share of Biodyne Co (314930.KQ) as of Nov 3, 2026 is -163.06 KRW. In the previous year, Free Cash Flow per Share was 11.48 KRW — a change of -1,520.97% (lower).

FCF per Share

-163.06KRW

YoY

-1,520.97%

Last updated:

Free Cash Flow per Share of Biodyne Co is 2025 -163.06 KRW. Free Cash Flow per Share of Biodyne Co was 2024 11.48 KRW. It decreases by -1,520.97% lower compared to the previous year.

The Biodyne Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-56.25 KRW
Jan 1, 2019
-1,528.18 KRW
Jan 1, 2020
-155.45 KRW
Jan 1, 2021
-227.99 KRW
Jan 1, 2022
195.69 KRW
Jan 1, 2023
-8.98 KRW
Jan 1, 2024
11.48 KRW
Jan 1, 2025
-163.06 KRW
The Biodyne Co FCF per Share history
YEARFCF per ShareYoY
-163.06KRW-1,520.97%
11.48KRW-227.79%
-8.98KRW-104.59%
195.69KRW-185.83%
-227.99KRW+46.67%
-155.45KRW-89.83%
-1,528.18KRW+2,616.65%
-56.25KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biodyne Co Stock analysis

What does Biodyne Co do? Biodyne Co., Ltd. develops and sells cancer diagnosis solutions, including LBC diagnostic equipment and diagnostic reagent kits. The company's equipment lineup features PATHPLORER AUTO, PATHPLORER 4.7, PATHPLORER 4.63, and PATHPLORER ECO, targeting healthcare providers in domestic and international markets. Products are sold in Japan, Russia, Portugal, and Thailand, with domestic sales complementing overseas distribution. Revenue is generated through direct sales of diagnostic equipment and reagent kits to medical facilities and laboratories. Biodyne's primary customers are healthcare institutions requiring cancer screening and diagnostic tools, including hospitals and clinical laboratories. The firm's domestic market presence supports its international expansion into regions like Japan and Russia, where demand for advanced diagnostic solutions is growing. Sales of PATHPLORER series equipment and reagent kits form the core revenue streams, with no additional services or licensing models mentioned. The company focuses on a niche segment of cancer diagnostics, leveraging its equipment and reagent kits to serve both local and global healthcare systems. By offering standardized diagnostic solutions, Biodyne caters to the needs of medical professionals seeking reliable and efficient cancer detection methods. International markets such as Portugal and Thailand represent key growth areas alongside established domestic operations. Biodyne Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biodyne Co stock

Free Cash Flow per Share of Biodyne Co is -163.06 KRW in 2025.

Free Cash Flow per Share of Biodyne Co changed from 11.48 KRW to -163.06 KRW, representing a -1,520.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Biodyne Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biodyne Co

All Key Metrics — Biodyne Co